A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

ConditionsRefractory Lupus Nephritis Myasthaenia Gravis Stiff Person Syndrome Rheumatoid Arthritis (RA)Multiple Sclerosis Dermatomyositis Systemic Sclerosis (SSc)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorKyverna Therapeutics

About this trial

The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).

This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).

Eligibility criteria

Qualifiers

Provided informed consent for the LTFU study

Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol

Disqualifiers

Not applicable

Trial design

Treatments tested in this trial

KYV-101

Treatment groups

70 Participants

are divided into 1 treatment group

Sponsors and collaborators

Kyverna Therapeutics

Lead sponsor

Source ClinicalTrials.gov